Table 2.
Antimicrobial resistances of PVL-SA isolates.
| Antimicrobial | Total, n (%) | MSSA, n (%) | MRSA, n (%) |
|---|---|---|---|
| Oxacillin | 5/21 (24) | 0/21 (0) | 5/21 (24) |
| TMP/SMX | 6/21 (29) | 5/21 (24) | 1/21 (5) |
| Erythromycin | 4/21 (19) | 2/21 (10) | 2/21 (10) |
| Tetracycline | 3/21 (14) | 2/21 (10) | 1/21 (5) |
| Clindamycin | 3/21 (14) | 2/21 (10) | 1/21 (5) |
| Rifampin | 3/18 (17) | 3/18 (17) | 0/18 (0) |
| Gentamycin | 1/21 (5) | 0/21 (0) | 1/21 (5) |
| Ciprofloxacin | 1/20 (5) | 0/20 (0) | 1/20 (5) |
| Levofloxacin | 1/21 (5) | 0/21 (0) | 1/21 (5) |
| Moxifloxacin | 0/21 (0) | 0/21 (0) | 0/21 (0) |
| Vancomycin | 0/21 (0) | 0/21 (0) | 0/21 (0) |
| Linezolid | 0/19 (0) | 0/19 (0) | 0/19 (0) |
| Teicoplanin | 0/21 (0) | 0/21 (0) | 0/21 (0) |
| Fusidic Acid | 2/21 (10) | 2/21 (10) | 0/21 (0) |
| Mupirocin | 0/6 (0) | 0/6 (0) | 0/6 (0) |
MSSA: methicillin-susceptible Staphylococcus aureus; MRSA: methicillin-resistant Staphylococcus aureus; TMP/SMX: trimethoprim/sulfamethoxazole.